Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278986 · ClinicalTrials.gov registry record · Early Phase 1
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
A Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT07278986 is a Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07278986, a Early Phase 1 study of Endometrial Cancer and Near Infrared Fluorescence Imaging, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
Conditions Studied
Interventions
- DRUG CYTALUX™ (pafolacianine)
- DEVICE 1788 4K Camera System with Advanced Imaging Modality
Study Locations (2)
Pennsylvania
- Abramson Cancer Center at Penn Medicine - Philadelphia
- University of Pennsylvania Gynecologic Oncology Department - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-18 |
| Est. Completion | 2029-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07278986
The ClinicalTrials.gov registry entry for NCT07278986 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which CYTALUX™ (pafolacianine) is the first listed.
NCT07278986 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07278986 about?
NCT07278986 is a clinical study titled "CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer". The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
What is the current status of trial NCT07278986?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-18. Estimated completion is 2029-02.
What conditions does trial NCT07278986 study?
This clinical trial studies the following conditions: Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies.
What interventions are being tested in trial NCT07278986?
The interventions under investigation include: CYTALUX™ (pafolacianine) (DRUG), 1788 4K Camera System with Advanced Imaging Modality (DEVICE).
Who is sponsoring clinical trial NCT07278986?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278986 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Weight Loss Intervention in People With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
COMPLETED · Early Phase 1
-
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
The Better, Harder, Faster, Stronger Study
RECRUITING
Explore more on PlainTrial
Endometrial Cancer
All registered trials for this condition
Near Infrared Fluorescence Imaging
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.